Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Keeps “Sector Perform” Rating at Royal Bank Of Canada

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “sector perform” rating reiterated by equities research analysts at Royal Bank Of Canada in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $737.00 price objective on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price objective indicates a potential downside of 1.73% from the company’s previous close.

Other equities analysts have also issued reports about the company. Wall Street Zen raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 20th. Sanford C. Bernstein upgraded shares of Regeneron Pharmaceuticals to a “hold” rating in a report on Wednesday, July 29th. Wells Fargo & Company lifted their price target on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a research report on Friday, July 31st. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, September 21st. Finally, Leerink Partners increased their price objective on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a research report on Monday, August 17th. Fourteen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $802.18.

Regeneron Pharmaceuticals Trading Down 0.3%

Shares of REGN stock traded down $2.27 on Tuesday, reaching $749.98. 520,624 shares of the stock were exchanged, compared to its average volume of 828,712. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The stock has a market cap of $77.22 billion, a P/E ratio of 18.54, a price-to-earnings-growth ratio of 1.54 and a beta of 0.20. The firm has a 50 day moving average of $781.41 and a two-hundred day moving average of $720.99. Regeneron Pharmaceuticals has a 1-year low of $541.00 and a 1-year high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. The firm’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same quarter last year, the firm earned $12.81 earnings per share. On average, research analysts anticipate that Regeneron Pharmaceuticals will post 44.25 EPS for the current year.

Insider Activity

In other news, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the sale, the director owned 603 shares in the company, valued at $512,550. This trade represents a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,131 shares of the business’s stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total transaction of $969,708.09. Following the transaction, the executive vice president directly owned 12,003 shares in the company, valued at approximately $10,291,252.17. The trade was a 8.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 4,146 shares of company stock worth $3,432,488 over the last three months. Insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $5,682,636,000. State Street Corp raised its holdings in Regeneron Pharmaceuticals by 3.6% in the second quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock valued at $3,014,621,000 after acquiring an additional 170,210 shares in the last quarter. Franklin Resources Inc. boosted its stake in Regeneron Pharmaceuticals by 4.4% during the 4th quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock valued at $1,975,990,000 after acquiring an additional 106,861 shares during the last quarter. Nuveen LLC increased its position in shares of Regeneron Pharmaceuticals by 71.1% in the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after purchasing an additional 835,240 shares during the last quarter. Finally, Invesco Ltd. raised its stake in shares of Regeneron Pharmaceuticals by 7.2% in the 4th quarter. Invesco Ltd. now owns 1,591,105 shares of the biopharmaceutical company’s stock valued at $1,228,127,000 after purchasing an additional 106,632 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Biohaven entered a clinical supply agreement to evaluate its cancer candidate BHV-1530 in combination with Regeneron’s Libtayo in patients with solid tumors, with enrollment underway. The collaboration could support Libtayo’s development and expand Regeneron’s oncology pipeline. Why Did Regeneron Pharmaceuticals Stock Drop Today?
• Neutral Sentiment: Regeneron’s third-quarter results are expected on October 30. Investors will likely focus on Eylea sales, broader pipeline progress and whether the company can maintain its strong earnings trajectory after its latest reported quarter beat expectations on both earnings and revenue. Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30?
• Neutral Sentiment: Royal Bank of Canada reaffirmed its “sector perform” rating and assigned a $737 price target, indicating limited near-term upside based on its valuation view. Separately, a value comparison with Illumina is drawing attention to REGN’s investment appeal, but does not represent a new company-specific catalyst. Royal Bank of Canada Rating REGN or ILMN Value Comparison
• Negative Sentiment: Kodiak Sciences reported positive Phase 3 DAYBREAK results for Zenkuda and tabirafusp alfa tedromer in wet age-related macular degeneration. The candidates met primary endpoints against Eylea while being administered approximately every six months, compared with Eylea’s roughly eight-week dosing schedule. The data raise the possibility of meaningful future competition for Regeneron’s key eye-care franchise and triggered the recent pullback in REGN shares. What Does Regeneron Need to Prove in Eye Disease?

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.